Alexza Pharmaceuticals

Roth Capital Cuts Alexza Pharmaceuticals Price Target Following Earnings

Roth Capital analyst Scott Henry maintained a Neutral rating on Alexza Pharmaceuticals (NASDAQ:ALXA), and reduced his price target to $2.50 (from $5.

Alexza: We believe In The Long-Term Potential, But We Will Choose To Be On The Sidelines, Says Roth Capital

In a research report published August 8, Roth Capital analyst Scott Henry downgraded shares of Alexza Pharmaceuticals (ALXA) from a Buy to a Neutral rating with …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts